Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Four years late, 50% success rate, Lilly’s solanezumab stays in PhIII

This article was originally published in Scrip

Executive Summary

The earliest possible date that solanezumab is likely to reach the US Alzheimer’s market is now the end of 2017, four years later than Eli Lilly had initially hoped when it started its EXPEDITION clinical trial program. Assuming approval in mild Alzheimer’s disease, with additional off-label use in MCI patients, Datamonitor forecasts solanezumab to achieve sales of $4.0 billion across the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) in 2021.

You may also be interested in...



Surprise! It’s A Phase III Failure

When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.

Will J&J TRANSFORM Esketamine Into A Viable Depression Treatment?

In early 2018 Johnson & Johnson is expecting to announce the first data from its long-awaited pivotal clinical trial program for esketamine in treatment-resistant depression; a successful result will open a lucrative commercial opportunity for J&J and give the wider depression market a new direction for growth.

If Alkermes Antidepressant Can Get Past FDA, The Market Might Be There

Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel